GeNeuro SA’s Post

Have you experienced #LongCovid symptoms, like difficulty remembering and concentrating? Which is the pathology mechanism that explains the #cognitive decline in #LongCOVID-19 patients? Is #NeuroPASC a risk factor for developing #Alzheimer’s disease in the future? This manuscript conclusion was: “The SARS-CoV-2 pandemic produced in its wake millions of persons affected with long Covid, some of whom have had or are currently having cognitive challenges. A deeper understanding of the biology of cognitive dysfunction after SARS-CoV-2 infection and how best to prevent and treat it are critical for addressing the needs of affected persons and preserving the cognitive health of populations”. The picture below indicates some possible understanding about the patho-mechanism of cognitive decline for LongCovid patients.

🔊Skin Test Detects Evidence of Parkinson's Disease Dr. Christopher Gibbons from Beth Israel Deaconess Medical Center explores new #biomarkers for diagnosing #Parkinson's disease and other #neurodegenerative disorders, known as synucleinopathies. Alpha-synuclein is a protein crucial to brain and nerve function. An abnormal version of this protein can accumulate and lead to serious diseases, including Parkinson's, #dementia with Lewy bodies, and multiple system atrophy. Unfortunately, traditional diagnostic methods rely heavily on specialist assessments, leaving a gap in accessible testing. Dr. Gibbons' team previously discovered that abnormal forms of alpha-synuclein could be detected in skin nerve fibers. They conducted a study with over 400 participants-277 diagnosed with one of the #synucleinopathies, and 151 healthy controls. Participants underwent small skin biopsies from the neck, knee, and ankle to test for the presence of phosphorylateo alpha-synuclein, known as P-SYN. The results were promising: the test detected P-SYN in 93% of participants with Parkinson's disease, 98% with multiple system atrophy, and 96% with Lewy body dementia. The biopsies also identified all cases of pure autonomic failure, and P-SYN levels correlated with disease severity. #NIH #Parkinson #healthcare #diagnosis #earlydetection #dementia #synuclein #NIHrecord #genomics

Summary: Researchers mapped disease trajectories from birth to death, analyzing over 44 million hospital stays in Austria to uncover patterns of multimorbidity across different age groups. Key Facts: Mapping Multimorbidity: The study identified 1,260 disease trajectories, underscoring the prevalence of multimorbidity and highlighting opportunities for early intervention. Critical Moments Identified: Analysis revealed crucial points where disease paths diverge, suggesting targeted prevention could significantly impact future health outcomes. Personalized Prevention: The research underscores the importance of early, personalized healthcare strategies to mitigate long-term health risks and reduce the burden on healthcare systems. Source: CSH For instance, young men with sleep disorders showed two different paths, indicating varying risks for developing metabolic or movement disorders later in life. These insights provide a powerful tool for healthcare professionals to implement targeted interventions, potentially easing the growing healthcare burden due to an aging population and improving individuals’ quality of life.

A common question we get is, "How is someone actually diagnosed with Parkinson's disease?" 🩺 Parkinson’s disease is a “clinical” diagnosis. This means that an individual’s history, symptoms, and physical exam are used to make the diagnosis. There is not a specific lab or imaging test that can diagnose PD. However, certain tests, such as an MRI, a DaT scan, or blood work can be used to support the diagnosis of PD or to rule out other medical conditions that can mimic PD. Learn more about the process of getting diagnosed with Parkinson's: https://lnkd.in/eCHvGutv

The incidence of brain tumor cases has been on the rise in our nation. Despite the potential for effective management through early detection and appropriate treatment, many individuals face heightened risks of mortality or disability due to limited awareness and inadequate access to advanced healthcare services. Fortunately, Medica’s Institute of Neurological Diseases stands ready with comprehensive resources to tackle this challenge head-on. Equipped with state-of-the-art facilities, they offer advanced treatment options for a wide range of brain tumors. By addressing these gaps in awareness and accessibility, we can enhance outcomes and improve the well-being of those affected by this condition. #BrainTumorAwareness #HealthcareAccess #AdvancedTreatment #NeurologicalHealth #MedicaInstitute #EarlyDetection #WellnessFirst #FightBrainTumors #RaiseAwareness #ImprovedOutcomes @followers

"Lewy body dementia is a progressive neurodegenerative disease that shares traits with both #ParkinsonsDisease and #AlzheimersDisease but can be more difficult to diagnose. Symptoms can include hallucinations, movement disorders, cognitive issues, sleep problems and #Depression." "To better understand how the disease develops, the Mayo Clinic's Yunjung Jin, Na Zhao, et al. created mini brain models in a dish that closely match key features seen in the brains of patients with #LewyBodyDementia." "The team also identified four potential drug compounds that may offer promising approaches to treating the disease." Learn More in Science Advances | Science Magazine https://lnkd.in/eCXEUScF Modeling Lewy body disease with SNCA triplication iPSC-derived cortical organoids and identifying therapeutic drugs - Yunjung Jin, Na Zhao, et al. Mayo Clinic University of Stellenbosch

Interesting read on the possible gut origins of Parkinson's Disease instead of in the brain. The latest research suggests an increase in its incidence as well. Worth taking a couple of minutes to read. [Link to the article] #ParkinsonsDisease #HealthResearch

High-risk #neurological phenotypes in adult-onset classic monogenic #autoinflammatory diseases (systematic review): 🔹N = 51 patients, median age was 38 years old and there was a male predominance (63%). 🔹Neurological manifestations occurred after a median disease duration of 5 years, although some cases presented at onset.  🔹The most common neurological symptom was headache, followed by symptoms of cranial nerve dysfunction, focal neurological deficits, and seizures.  🔹Predominant phenotypes included #stroke for #DADA2 patients, #demyelinating lesions and #meningitis for familial mediterranean fever, and meningitis for #CAPS. #TRAPS had insufficient data for adequate phenotype characterization. 🔗https://lnkd.in/e6jvGDnr

In an important development for healthcare professionals, new blood tests have emerged that can help diagnose Alzheimer's disease. These tests provide a fast and convenient way for physicians to determine whether a patient exhibiting symptoms of cognitive decline also has the characteristic brain changes associated with Alzheimer's. #Alzheimers #MedicalInnovation #DiagnosticTests #PatientCare https://lnkd.in/epq_n_GB